IMTX (Immatics NV) Beta: 1.6714 (As of Jun. 25, 2026)


IMTX Immatics NV IMTX
60 GF Score
Price $10.20
GF Value $3.57
Valuation Significantly Overvalued
! 4 Warning Signs
View Full Analysis

What is Immatics NV Beta?

Immatics NV IMTX +1.80% 60 Beta is 1.6714 as of Jun. 25, 2026. GuruFocus rates IMTX with a GF Score™ of 60/100 and a GF Value™ of $3.57 (Significantly Overvalued). The stock has 4 warning signs investors should review.

Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. As of today (2026-06-25), Immatics NV's Beta is 1.6714.


Immatics NV  (NAS:IMTX) Beta Explanation

Beta is a measure of the volatility, or systematic risk, of a security or a portfolio in comparison to the market as a whole. We usually compare beta to 1. A beta of 1 indicates that the security's price will move with the market. A beta of less than 1 means that the security will be less volatile than the market. A beta of greater than 1 indicates that the security's price will be more volatile than the market.

Beta is primarily used in the Capital Asset Pricing Model (CAPM) to calculate the Cost of Equity, which can be used in the calculation of WACC %. The formula of Cost of Equity is:
Cost of Equity = Risk-Free Rate of Return + Beta of Asset * (Expected Return of the Market - Risk-Free Rate of Return)


Immatics NV Beta Related Terms


Immatics NV Beta Historical Data

* Premium members only.

The historical data trend for Immatics NV's Beta can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Immatics NV Beta Chart

Immatics NV Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Beta
Get a 7-Day Free Trial 0.00 0.00 1.33 1.20 1.41

Immatics NV Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Beta Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.92 1.37 1.41 1.41 1.58

IMTX vs INVA, PGEN, VIR: Beta Comparison

For the Biotechnology subindustry, Immatics NV's Beta, along with its competitors' market caps and Beta data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Immatics NV Beta vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Immatics NV's Beta distribution charts can be found below:

* The bar in red indicates where Immatics NV's Beta falls into.


IMTX
60GF Score
Immatics NV IMTX
Beta is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Immatics NV Beta Calculation

Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. A stock's beta can be calculated by dividing the product of the covariance of the individual stock's returns and the market's returns by the variance of the market's returns over a specified period. Basically, GuruFocus uses the returns calculated over three-year period.

Frequently Asked Questions Learn more about Beta →
What does a Beta of 1.6714 mean?
Immatics NV (IMTX) has a Beta of 1.6714 as of Jun. 25, 2026. Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. View historical data for Immatics NV and its competitors.
Is Immatics NV's Beta too high?
Immatics NV's current Beta is 1.6714. Overall, Immatics NV has a GF Score™ of 60/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Immatics NV's Beta compare to INVA and PGEN?
Immatics NV's Beta of 1.6714 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beta for a Biotechnology company?
A good Beta depends on the Biotechnology industry context. However, Beta should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beta mean?
A high Beta can signal that a stock is expensive relative to its fundamentals. Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. View historical data for Immatics NV and its competitors. Immatics NV's current Beta is 1.6714. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Immatics NV stock overvalued right now?
Based on GuruFocus' analysis, Immatics NV (IMTX) is currently considered Significantly Overvalued. The stock's GF Value™ is $3.57, compared to a current price of $10.20 — trading 185.7% above its estimated fair value. The current Beta is 1.6714. Immatics NV's overall GF Score™ is 60/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beta calculated?
Beta is calculated from a company's financial statements. For Immatics NV (IMTX), the current Beta is 1.6714 as of Jun. 25, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Immatics NV (IMTX) Overvalued in 2026?

Based on GuruFocus' analysis, Immatics NV stock appears to be overvalued. The current stock price of $10.20 is trading 185.7% above its estimated GF Value™ of $3.57. GuruFocus considers Immatics NV to be Significantly Overvalued.

Key valuation signals for IMTX:

  • Beta: 1.6714
  • GF Value™: $3.57 vs. price of $10.20 (185.7% above fair value)
  • GF Score™: 60/100 with 4 warning signs

No single metric tells the full story. See the IMTX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Immatics NV Business Description

Other Exchanges 4A3:Germany
Address Paul-Ehrlich-Strasse 15, Tubingen, BW, DEU, 72076
Immatics NV is a clinical-stage biotechnology company engaged in the research and development of T-cell redirecting immunotherapies for the treatment of cancer patients. The company earns revenue through strategic collaboration agreements with third-party pharmaceutical and biotechnology companies. The company derives its maximum revenue from United States.
60GF Score

Get the complete analysis for IMTX

Beta is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$10.20
Price
$3.57
GF Value